StockData
CapsoVision, Inc logo

CapsoVision, Inc (CV) stock

CVNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30733% above fair value
$6.65+0.18 (+2.78%)

Close on Nov 17, 2026Market cap $332.81MP/E –Yield –

CapsoVision r&d expenses

Research and development expenses are spending on new products and technology.

CapsoVision's R&D Expenses for the twelve months ending Jun 30, 2026 was $21.56M, up 52.5% year over year. For fiscal 2025 it was $18.31M, up 21.1% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.31M+21.1%
FY2024Dec 31, 2024$15.12M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.31M+56.5%
Q1 FY2026Mar 31, 2026$4.44M+42.7%
Q4 FY2025Dec 31, 2025$5.72M+83.6%
Q3 FY2025Sep 30, 2025$6.09M+34.7%
Q2 FY2025Jun 30, 2025$3.39M-19.7%
Q1 FY2025Mar 31, 2025$3.11M–
Q4 FY2024Dec 31, 2024$3.12M–
Q3 FY2024Sep 30, 2024$4.52M–
Q2 FY2024Jun 30, 2024$4.22M–

More CapsoVision figures

See a number that looks wrong?